X4 Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

BOSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. XFOR, a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will conduct one-on-one investor meetings at the Citi 16th Annual BioPharma Conference and participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference.

Details are as follows:

Conference: Citi 16th Annual BioPharma Conference

Date: September 8 – 10, 2021

1x1 meetings only

Conference: H.C. Wainwright 23rd Annual Global Investment Conference

Date: Monday, September 13, 2021

Time: 7:00 AM ET

Fireside Chat Webcast Link

A live webcast of the H.C. Wainwright 23rd Annual Global Investment Conference fireside chat will be available on the investor section of the X4 Pharmaceuticals website at www.x4pharma.com. The event will remain archived on the X4 Pharmaceuticals' website for approximately 90 days.

About X4 Pharmaceuticals

X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases of the immune system resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company's lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a number of clinical trials, including a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenström's macroglobulinemia, and as monotherapy in patients with Severe Congenital Neutropenia and other chronic neutropenia disorders. X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. For more information, please visit www.x4pharma.com.

Investors and Media: 

Daniel Ferry

Managing Director

LifeSci Advisors

daniel@lifesciadvisors.com

(617) 430-7576

Mónica Rouco Molina

Senior Account Executive

LifeSci Communications

mroucomolina@lifescicomms.com